{"id":"nct:NCT07481747","kind":"trial","title":"Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)","authors":["Hudson Biotech"],"author_count":1,"year":2026,"published":"2026-03-19","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07481747","source_url":"https://clinicaltrials.gov/study/NCT07481747","archive_url":"https://space-kitty.com/papers/nct:NCT07481747","updated":"2026-03-19","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased physical activity, in adults without type 2 diabetes who have obesity or are overweight with weight-related comorbidities. The primary efficacy assessment is at Week 72. Participants with prediabetes at randomization may continue in an additional long-term treatment period to assess progression to type 2 diabetes and longer-term weight outcomes.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Obesity","Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities"],"details":{"acronym":"SURMOUNT-1","status":"RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":2539,"sponsor":"Hudson Biotech","conditions":["Obesity","Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities"],"interventions":["DRUG: Tirzepatide","DRUG: Placebo","BEHAVIORAL: Reduced-calorie diet"],"start_date":"2026-02-02","start_date_type":"ACTUAL","primary_completion_date":"2027-02-14","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[]}